title: Whether lithium inhibits glycogen synthase kinase (GSK)-3β activity in vivo in humans is still an open question.
authors.affiliation: Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.|Psychiatry Research Unit, Ben-Gurion University of the Negev, Beer-Sheva, Israel.|Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
authors.forename: Galila
authors.initials: G
authors.lastname: Agam
authors.affiliation: Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.|Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.|School for Community Health Professions, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
authors.forename: Abed N
authors.initials: AN
authors.lastname: Azab
mesh_terms: D018692:Antimanic Agents; D001714:Bipolar Disorder; D038362:Glycogen Synthase Kinase 3; D006801:Humans; D008094:Lithium; D010766:Phosphorylation
chemical_list: D018692:Antimanic Agents; D008094:Lithium; D038362:Glycogen Synthase Kinase 3
keywords: bipolar disorder; glycogen synthase kinase (GSK)-3β; lithium; therapeutic mechanism